NRNicolaus Reifart

Nicolaus Reifart

*This is an algorithmically generated author record based on publicly available information.

Nicolaus Reifart has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Challenges in Complicated Coronary Chronic Total Occlusion Recanalisation

    by Nicolaus Reifart

    Percutaneous coronary intervention for chronic total occlusions (CTOs) is still today a challenge even for experienced operators. In the hands of the most experienced the success rate increased from about 60 to 90 % in the past 10 years; paralleled by a long-term patency with drug-eluting stents exceeding 90 %. These results are comparable or even superior to surgical revascularisation. Thanks to Japanese and European CTO club online registries and live courses we are able to rapidly understand and adopt new strategies, techniques and materials to master morphology deemed untreatable 10 years ago. Several of the persistent challenges and solutions unique to CTO interventions are discussed.


  • Percutaneous Revascularisation of Coronary Chronic Total Occlusion – Outcomes and Development of Strategy 2006–2010

    by Nicolaus Reifart

    Percutaneous coronary intervention for chronic total occlusions (CTOs), the most difficult and time-consuming intervention, is evolving rapidly. There has been a well-documented increase in the success rate of procedures in the hands of specifically trained operators from about 60 % to 90 % over the past 10 years; at the same time, the long-term patency with drug-eluting stents is exceeding 90 %. These results are comparable or even superior to surgical revascularisation. Several sophisticated techniques unique to CTO interventions are described in this article, and the need for specific training is emphasised so that a success rate of at least 80 % can be met, as claimed by the European Society of Cardiology guidelines on myocardial revascularisation, and so that patients with CTO who deserve revascularisation are no longer denied appropriate treatment.


  • Short and long term comparison (24 months) of an alternative sirolimus-coated stent with bioabsorbable polymer and a bare metal stent of similar design in chronic coronary occlusions: the CORACTO trial

    by Nicolaus Reifart, Karl-Eugen Hauptmann, Alexander Rabe, Darius Enayat, Kiriakos Giokoglu

    We studied a novel sirolimus eluting stent with a bioabsorbable coating (SES) in >3 months old chronic total coronary occlusions (CTO). Ninety-five patients were randomised to either BMS (n=47) or SES (n=48). The primary endpoints were late lumen loss (LLL) and in-segment restenosis (ISR) after six months. Secondary endpoints were target vessel revascularisation after six and 24 months. Occlusion length (37.6 mm), reference diameter (2.8 mm) as well as the stented segment (45.5 mm) were similar in both groups. Up until six months no death, myocardial infarction or stent thrombosis occurred in either group. Angiographic follow-up (45BMS/46SES): LLL 1.8 mm/0.77 mm (p<0.0001), ISR 60%/17.4% (p<0.0001). In-segment re-occlusion 15.5%/0% and TVR 53.3%/10.8% (p<0.0001). After 24 months: 1 BMS, 2 SES patients died; 0 BMS, 0 SES infarction; 0 BMS, 0 SES stent thrombosis and 3 BMS, 0 SES TVR between six and 24 months. Thus total TVR after 24 months was 60% for BMS and 10.8% for SES (p<0.0001). The alternative sirolimus-coated stent was shown to reduce the relative risk of restenosis after six months by 71%, and of TVR after 24 months by 82%. Between six and 24 months, neither stent thrombosis occurred, nor repeat revascularisation was required in patients who received a SES.


    • 1 May 2009
      • p. D127-30

    Percutaneous in situ venous arterialisation.

    by Nicolaus Reifart

    About 5% of patients annually have no acceptable therapeutic option because of diffuse coronary disease without a discrete target for angioplasty, stenting or surgical bypass. Retrograde perfusion of the myocardium via the venous system was successfully performed by cardiac surgeons before the widespread use of coronary artery bypass grafting and has been applied in "ungraftable" patients since. Percutaneous in situ venous arterialisation (PICVA) follows this surgical experience, using a series of unique catheter-based devices to arterialise isolated segments of coronary vein to provide retrograde perfusion of the ischaemic myocardium. In a series of animals this procedure had been shown to reduce ischaemia and myocardial damage in an infarction model. In the PICVA European Safety trial, the first eleven percutaneous applications of catheter-based, coronary bypass in humans revealed feasibility of the technique in highly symptomatic, non-option patients. Despite two deaths and six failures to create a connection, we continue to believe that upon further development, the catheter-based veno-arterial coronary bypass can become an option in inoperable and undilatable patients.

  • Percutaneous In Situ Coronary Venous Arterialization: A Catheter‐Based Procedure for Coronary Artery Bypass

    by Nicolaus Reifart

    Diffuse coronary artery disease is frequently untreatable by coronary artery bypass or angioplasty. Open chest surgical arterialization of the coronary venous system was successfully performed before the widespread use of coronary artery bypass grafting and has been applied in ungraftable patients thereafter. Percutaneous in situ coronary venous arterialization (PICVA™) follows this surgical experience, using a series of unique catheter‐based devices to arterialize isolated segments of coronary vein, forcing retroperfusion of severely ischemic myocardium. In a series of animals, this procedure had been shown to reduce ischemia and myocardial damage in an infarction model. In the PICVA European Safety trial, the first 11 percutaneous applications of catheter‐based coronary bypass in humans revealed feasibility of the technique in highly symptomatic “no‐option” patients. Despite two deaths and six failures to create the bypass, we continue to believe that on further development, the catheter‐based coronary bypass can become a broad‐based interventional application.

  • The NUGGET study: NIR ultra gold‐gilded equivalency trial

    by Nicolaus Reifart, Marie‐Claude Morice, Sigmund Silber, Edouard Benit, K.E. Hauptmann, Eduardo de Sousa, John Webb, Upendra Kaul, Charles Chan, Leif Thuesen, et al.

    This study should clarify whether the gold‐coated NIROYAL stent is equivalent to the stainless steel NIR stent. Patients were randomized to either NIR stent (n = 298) or a NIROYAL stent (n = 305). The primary endpoint was the minimum lumen diameter of the target lesion at 6 months postprocedure. Secondary endpoints focused on clinical events. At 30 days, adverse events were similar in both groups. At 6 months, the minimal lumen diameter was 1.83/1.64 mm (P < 0.001; 95% CI = 0.08–0.30) and the angiographic restenosis rate was 20.6%/37.7% (P < 0.001; 95% CI = −24.7 to −9.3) for NIR/NIROYAL. The 6‐month MACE rates were NIR 7.4% and NIROYAL 10.5% (95% CI = −7.7 to 1.4). Compared to stainless steel stent, the NIROYAL stent demonstrated a smaller minimal lumen diameter, a higher late loss (i.e., higher neointimal hyperplasia in spite of a significantly better initial gain), with higher restenosis and similar MACE rates at 6 months. Catheter Cardiovasc Interv 2004;62:18–25.